Tweet
"RegeneRx Biopharmaceuticals, Inc. announced today the publication of the first human data from a case study of patients evaluated with its ophthalmic product candidate RGN-259.
"The data have been published in the May 2010 issue of Archives of Ophthalmology, an American Medical Association peer-reviewed journal. In one case, a patient had a non-healing wound for nearly 14 months. The patients were treated for 28 days with RGN-259 and evaluated 28 days after treatment. Three of the patients experienced complete healing of their wounds, with substantial healing in the fourth patient. There were no drug-related adverse events and all patients reported reduced ocular irritation."
"Dr. Dunn and his colleagues are planning a Phase 2 study with RGN-259 in patients with dry eye associated with graft vs. host disease later this year that will be supported, in part, by RegeneRx."
"The data have been published in the May 2010 issue of Archives of Ophthalmology, an American Medical Association peer-reviewed journal. In one case, a patient had a non-healing wound for nearly 14 months. The patients were treated for 28 days with RGN-259 and evaluated 28 days after treatment. Three of the patients experienced complete healing of their wounds, with substantial healing in the fourth patient. There were no drug-related adverse events and all patients reported reduced ocular irritation."
"Dr. Dunn and his colleagues are planning a Phase 2 study with RGN-259 in patients with dry eye associated with graft vs. host disease later this year that will be supported, in part, by RegeneRx."